A fit for purpose approach has been
adopted in order to develop
a robust, scalable route to the S1P1 receptor agonist,
GSK2263167. The key steps include a Robinson ring annulation followed
by a Saegusa oxidation, providing rapid access to an advanced phenol
intermediate. Despite the use of stoichiometric palladium acetate
for the Saegusa oxidation, near complete recovery of the palladium
has been demonstrated. The remaining steps have been optimised including
the removal of all chromatography. An alternative to the Saegusa oxidation
is described as well as the development of a flow process to facilitate
further scale-up of the amidoxime preparation using hydroxylamine
at elevated temperature.